The recently published outcomes of the ProtecT trial showed no difference in PCa-specific survival after a median of 10 yr follow-up between surgery (RP), radiotherapy (RT) and active monitoring (AM) in men with screen detected localized prostate cancer (PCa) [1]. However, data also showed a higher rate of metastatic (Mþ) PCa in the AM arm. Caveat of ProtecT are the randomization of PCa cases into the AM arm that are considered high risk and the AM protocol which is substantially different from current Active Surveillance (AS) protocols.
INTRODUCTION AND OBJECTIVES: DNA repair gene mutations are important molecular alterations in prostate cancer pathogenesis. Germline mutations in DNA repair genes, particularly BRCA2, were recently recognized as associated with metastatic prostate cancer. Prostate tumors with DNA repair defects may also be particularly sensitive to platinum based chemotherapy and PARP inhibitor therapy. We sought to characterize alterations in DNA repair pathway genes in both primary and metastatic prostate tumors.
METHODS: We studied the distribution of DNA repair gene mutations in 936 prostate cancers harvested from localized and metastatic tumors. Tumor DNA underwent hybrid capture for all coding exons of 395 cancer-related genes plus select introns from 19 or 31 genes frequently rearranged in cancer. Captured libraries were sequenced to a median exon coverage depth of >500x using Illumina sequencing and were analyzed for base substitutions/insertions, copy number alterations and rearrangements. We utilized two described lists of genes involved in DNA repair : our own in-house list of 74 (UCD) and a list of 20 DNA repair genes associated with cancer predisposition syndromes utilized in a recent publication by Pritchard et al. Nine genes were in common between the two lists yielding a total of 85 unique DNA repair genes. We further stratified the frequency of mutations by tissue site (prostate versus metastases). Only tissues represented by at least 10 samples in the set were included (868). Frequencies of DNA repair defects were compared across metastatic sites by Pearson's Chisquared test.
RESULTS: We identified 228/936 unique samples with at least one likely functional mutation in a DNA repair gene (24.4%). Mutations were identified in 20.1% of prostate tumors (13% UCD, 18.4% Pritchard et al.) and in 18.8% of bone metastases. The highest rates of DNA repair mutations were found in visceral metastases including brain, pelvis and liver, which were significantly higher than either prostate tissue or bone sites (p¼<0.01). The most commonly (¼1% of samples) mutated genes in the DNA repair pathways are: BRCA2 (11.43%), ATM (5.77%), MSH6 (2.46%), MSH2 (2.14%), ATR (1.60%), MLH1 (1.28%), and BRCA1 (1.18%).
CONCLUSIONS: DNA repair gene mutations are more common in metastatic than localized prostate tumors. Visceral metastases appear enriched for these mutations compared with localized tumors or bone and lymph node metastases. Genomic profiling may identify prostate cancers potentially sensitive to platinum-based chemotherapy or PARP inhibition. (Abdollah et al. JCO 2014) . The aim of this study was to assess whether the rate of other cause mortality (OCM) differs in Nþ PCa patients according to these 5 risk-groups, after accounting for the risk of cancer specific mortality (CSM). This would allow to improve patient stratification and to identify candidates for additional therapies.
METHODS: We evaluated 1,312 Nþ PCa patients treated with radical prostatectomy and pelvic lymph node dissection at two tertiary referral centers between 1988 and 2014. Patients were stratified into the 5 established risk-groups: very low-risk (2 Nþ, and Gleason score 6); low-risk (2 Nþ, Gleason score 7-10, pT2/pT3a and negative surgical margins); intermediate-risk (2 Nþ, Gleason score 7-10 and pT3b/pT4 or SMþ); high-risk (3-4 Nþ); very high-risk (>4 Nþ). Poisson smoothed cumulative incidence methods were used to assess 8-year OCM according to risk groups, after accounting for the risk of CSM. The same analyses were performed among men who experienced BCR after RP (n¼ 633, 48.2%).
RESULTS: The median follow-up after RP was 82 months (IQR 37.1-147). During the study period, 18.1% of men died from other causes and 14.6% died from PCa. The leading cause of death at 8-year was OCM in the very low and low risk groups (12.6 and 8.3% vs. 2.5 and 7.6% for CSM, respectively). Conversely, CSM was the main cause of death in the remaining groups (Fig 1a) . When the same analyses were repeated in men who had BCR after RP, CSM was the leading cause of death in all risk-groups except in very low-risk patients, where the 8-year OCM and CSM were similar (5.9 and 5.8%, respectively; Fig. 1b) .
CONCLUSIONS: PCa is not invariably the main cause of death in all Nþ patients treated with curative intent. Patients with less aggressive disease are more likely to die from other causes. Conversely, when Nþ patients recur, they will likely succumb from PCa rather than from other causes, regardless of tumor aggressiveness. These results could help physicians sparing unnecessary treatments in Nþ men with lower likelihood of dying from PCa and to plan timely salvage treatments in virtually all Nþ men who recur Source of Funding: none
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Rashid Sayyid*, Shabbir Alibhai, Rinku Sutradhar, Maria Eberg, Kinwah Fung, David Urbach, Neil Fleshner, Toronto, Canada INTRODUCTION AND OBJECTIVES: Transrectal ultrasoundguided prostate biopsies (TRUS-Bx) have a high false-negative rate, and thus men with a negative TRUS-Bx frequently undergo repeat biopsies leading to subsequent diagnoses of prostate cancer (PCa). Long-term outcome data on such patients is lacking, as previous studies have only reported the short-term rates of PCa diagnosis in small cohorts of men with a negative TRUS-Bx. Our objective was to determine both the long-term rates of PCa diagnosis and all-cause mortality in a large, population-based cohort of men with a single negative TRUS-Bx.
METHODS: This was a retrospective, population-based study of 124,067 men who had an initially negative TRUS-Bx in Ontario, Canada between April 1994 and March 2015. All included men were older than 40 years and had no prior history of PCa. Using data from the Ontario Health Insurance Plan, Ontario Cancer Care Registry, and Registered Persons Database, housed at the Institute of Clinical and Evaluative Sciences, we were able to determine the 5, 10, 15, and 20 year rates of PCa diagnosis and all-cause mortality in such men.
RESULTS: Mean age at date of first negative TRUS-Bx was 63.55 years (SD¼8.75). Total follow-up time was 974986.07 person-years, with mean follow-up per patient at 7.86 years (SD¼5.37). The total number of subsequent PCa diagnoses was 21,869, accounting for an incidence rate of 22.25 per 1000 person-years. The 5, 10, 15, and 20-year rates of PCa diagnosis were 0.130, 0.187, 0.220, and 0.239, respectively. The total number of deaths in our cohort was 21,375, accounting for a death incidence rate of 21.92 per 1000 person-years. The 5, 10, 15, and 20-year all-cause mortality rates were 0.068, 0.155, 0.260, and 0.380, respectively.
CONCLUSIONS: Based upon these long-term populationbased data, a significant proportion of men with an initially negative TRUS-Bx subsequently receive a diagnosis of PCa, with risk of diagnosis continuously rising. These data suggest that long term follow up of at risk men is warranted. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e57
